Skip to content

Reported May 12, 2026 · Before market open

EPS-$0.52Miss by $0.12
EPS estimate-$0.40

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.43

Financials

Q1 2026

Income statement

See full
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$776.77M+42.7%
Enterprise value$500.33M+16.8%

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Versus estimates

Ask the moment Solid Biosciences Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Solid Biosciences Inc. report Q1 2026 earnings?
Solid Biosciences Inc. (SLDB) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Solid Biosciences Inc.'s Q1 2026 revenue and EPS?
Solid Biosciences Inc. reported eps of $-0.52 for Q1 2026.
Did Solid Biosciences Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.40 by $0.12.
How did Solid Biosciences Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 11.9% from $-0.59.
Where can I find Solid Biosciences Inc.'s Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001193125-26-219337) directly on SEC EDGAR. The filing index links above go to sec.gov.